Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Conclusions Narnatumab was well tolerated and showed limited antitumor activity with this dosing regimen.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research